Prostate Cancer Clinical Trials in Illinois

Showing 241-260 of 319 trials

Tivantinib in Treating Patients With Metastatic Prostate Cancer

NCT01519414

This randomized phase II trial studies how well tivantinib works compared to placebo in treating patients with metastatic prostate cancer. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Hormone-Resistant Prostate CancerProstate AdenocarcinomaRecurrent Prostate Carcinoma+1 more

National Cancer Institute (NCI)78 participantsStarted Jan 2012

Washington D.C., District of Columbia, United States • Tampa, Florida, United States • Chicago, Illinois, United States +17 more locations

COMPLETEDPhase 384 miles

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

NCT01605227

This study will evaluate the effect of cabozantinib compared to prednisone on overall survival in men with previously treated metastatic castration-resistant prostate cancer with bone-dominant disease who have experienced disease progression on docetaxel-containing chemotherapy and abiraterone or MDV3100.

Prostate CancerCastration Resistant Prostate CancerPain+1 more

Exelixis1,028 participantsStarted Jul 2012

Birmingham, Alabama, United States • Anchorage, Alaska, United States • Phoenix, Arizona, United States +261 more locations

Tivantinib in Treating Patients With Metastatic Prostate Cancer

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Prostate Cancer Trials in Other Cities

Abiraterone Post Ketoconazole for Prostate Cancer

Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer

Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

CHESS: Human and Computer Mentors for Prostate Cancer Patients

Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer

Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis

Vidaza to Restore Hormone Thx Prostate

Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer

Health-Related Quality of Life in Gay Men With Localized Prostate Cancer

Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer

ClariCore System Used in Transrectal Ultrasound Guided Prostate Biopsy for Real-Time Tissue Evaluation

An Open-label Extension Study of PSMA ADC 2301 in mCRPC

Other Conditions in Illinois